IDDA Stock Overview
A biotechnology company, develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.45 |
| 52 Week High | €2.72 |
| 52 Week Low | €1.34 |
| Beta | 0.87 |
| 11 Month Change | -10.49% |
| 3 Month Change | -25.64% |
| 1 Year Change | -30.95% |
| 33 Year Change | -63.93% |
| 5 Year Change | n/a |
| Change since IPO | -67.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDDA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.2% | -0.7% | -0.02% |
| 1Y | -31.0% | -17.2% | 8.2% |
Return vs Industry: IDDA underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: IDDA underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| IDDA volatility | |
|---|---|
| IDDA Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IDDA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IDDA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 168 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
| IDDA fundamental statistics | |
|---|---|
| Market cap | €124.02m |
| Earnings (TTM) | -€34.05m |
| Revenue (TTM) | €33.79m |
3.7x
P/S Ratio-3.6x
P/E RatioIs IDDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDDA income statement (TTM) | |
|---|---|
| Revenue | €33.79m |
| Cost of Revenue | €53.65m |
| Gross Profit | -€19.86m |
| Other Expenses | €14.20m |
| Earnings | -€34.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | -0.42 |
| Gross Margin | -58.77% |
| Net Profit Margin | -100.78% |
| Debt/Equity Ratio | 121.3% |
How did IDDA perform over the long term?
See historical performance and comparison